Effect of a Very Low-Calorie Ketogenic Diet on Gut Microbiota and Fat Distribution
Very Low-calorie Ketogenic Diet (VLCKD) Influences Taxonomic Composition of the Gut Microbiota and Visceral Adipose Tissue Distribution in Obese Patients With Type 2 Diabetes or Prediabetes Depending on Protein Source
1 other identifier
interventional
50
1 country
1
Brief Summary
Short-term interventions that use very low-calorie ketogenic diets and meal replacements may be prescribed for selected overweight or obese patients with type 2 diabetes or prediabetes. Few, inconsistent data are available on protein intake from various sources on body weight, the composition of gut microbiota and metabolic outcomes in these patients. The aim of the present study is to compare efficacy, safety and effect on microbiota composition of short-term isocaloric VLCKDs using whey proteins, vegetable proteins or animal proteins in obese patients with diabetes or prediabetes. 50 obese diabetic/prediabetic patients will be randomly assigned to three isocaloric VLCKD regimens (≤800 kcal/day) containing either whey, plant or animal proteins for 45 days. Outcome measures will be anthropometric parameters, vital signs, metabolic profile, body composition and microbiota assessment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable obesity
Started Jul 2019
Shorter than P25 for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2019
CompletedFirst Submitted
Initial submission to the registry
July 5, 2019
CompletedFirst Posted
Study publicly available on registry
July 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2019
CompletedMay 17, 2022
May 1, 2022
3 months
July 5, 2019
May 16, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Body Mass Index change from baseline
Body Mass Index will be calculated at baseline and after 45 days
45 days
Secondary Outcomes (9)
Fat mass percentage (%) change from baseline
45 days
Visceral adipose tissue (gr) change from baseline
45 days
Microbiome taxonomic composition change from baseline
45 days
Fasting glucose level (mg/dL) change from baseline
45 days
Fasting Insulin level (mcU/mL) change from baseline
45 days
- +4 more secondary outcomes
Study Arms (3)
Whey protein
EXPERIMENTALVLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
Vegetable proteins
ACTIVE COMPARATORVLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
Animal proteins
ACTIVE COMPARATORVLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
Interventions
meal replacements or animal protein
Eligibility Criteria
You may qualify if:
- obesity (BMI 30-40)
- newly-diagnosed and untreated type 2 diabetes (fasting plasma glucose ≥ 126 mg/dL or HbA1c ≥ 6.5 mmol/L) or impaired fasting glycemia (fasting plasma glucose from 110mg/dl to 125mg/dl).
- stable body weight in the previous 3 months
You may not qualify if:
- known hypersensitivity to one or more components used in the protocol products; history of renal, cardiac, cerebrovascular or gastrointestinal diseases; psychiatric disturbances; hydroelectrolytic alterations, diagnosis of type 1 diabetes lack of informed consent; history of or planned weight loss surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sapienza University of Rome
Roma, RM, 00161, Italy
Related Publications (1)
Basciani S, Camajani E, Contini S, Persichetti A, Risi R, Bertoldi L, Strigari L, Prossomariti G, Watanabe M, Mariani S, Lubrano C, Genco A, Spera G, Gnessi L. Very-Low-Calorie Ketogenic Diets With Whey, Vegetable, or Animal Protein in Patients With Obesity: A Randomized Pilot Study. J Clin Endocrinol Metab. 2020 Sep 1;105(9):dgaa336. doi: 10.1210/clinem/dgaa336.
PMID: 32484877DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lucio Gnessi, MD PhD
University of Roma La Sapienza
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
July 5, 2019
First Posted
July 15, 2019
Study Start
July 1, 2019
Primary Completion
October 1, 2019
Study Completion
November 1, 2019
Last Updated
May 17, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share